| 2009 |
Kanis JA, Oden A, Johansson H, Borgström F, Ström O, McCloskey E. FRAX® and its applications to clinical practice. Bone. May 2009;44(5):734-743. |
39 |
33 |
| 2020 |
Söreskog E, Ström O, Spångéus A, Åkesson KE, Borgström F, Banefelt J, Toth E, Libanati C, Charokopou M. Risk of major osteoporotic fracture after first, second and third fracture in Swedish women aged 50 years and older. Bone. May 2020;134:115286. |
2 |
0 |
| 2021 |
Malle O, Borgstroem F, Fahrleitner-Pammer A, Svedbom A, Dimai SV, Dimai HP. Mind the gap: incidence of osteoporosis treatment after an osteoporotic fracture: results of the Austrian branch of the International Costs and Utilities Related to Osteoporotic Fractures Study (ICUROS). Bone. January 2021;142:115071. |
1 |
1 |
| 2021 |
Talevski J, Sanders KM, Busija L, Beauchamp A, Duque G, Borgström F, Kanis JA, Svedbom A, Stuart AL, Brennan-Olsen S. Health service use pathways associated with recovery of quality of life at 12-months for individual fracture sites: analyses of the International Costs and Utilities Related to Osteoporotic fractures study (ICUROS). Bone. March 2021;144:115805. |
0 |
0 |
| 2021 |
Talevski J, Sanders KM, Busija L, Beauchamp A, Duque G, Borgström F, Kanis JA, Svedbom A, Connaughton C, Stuart AL, Brennan‐Olsen SL. Health service use and quality of life recovery 12 months following major osteoporotic fracture: latent class analyses of the international costs and utilities related to osteoporotic fractures study (icuros). J Bone Miner Res. February 2021;36(2):252-261. |
0 |
0 |
| 2008 |
Kanis JA, McCloskey EV, Johansson H, Strom O, Borgstrom F, Oden A. Case finding for the management of osteoporosis with FRAX®: assessment and intervention thresholds for the UK. Osteoporos Int. October 2008;19(10):1395-1408. |
26 |
16 |
| 2020 |
Söreskog E, Borgström F, Shepstone L, Clarke S, Cooper C, Harvey I, Harvey NC, Howe A, Johansson H, Marshall T, O’Neill TW, Peters TJ, Redmond NM, Turner D, Holland R, McCloskey E, Kanis JA; SCOOP study team. Long-term cost-effectiveness of screening for fracture risk in a UK primary care setting: the SCOOP study. Osteoporos Int. August 2020;31(8):1499-1506. |
0 |
0 |
| 2021 |
Söreskog E, Lindberg I, Kanis JA, Åkesson KE, Willems D, Lorentzon M, Ström O, Berling P, Borgström F. Cost-effectiveness of romosozumab for the treatment of postmenopausal women with severe osteoporosis at high risk of fracture in Sweden. Osteoporos Int. March 2021;32(3):585-594. |
0 |
0 |